Developing First-In-Class INPP5A Inhibitors as the First Effective Therapy for All GNAQ/11 Mutated Metastatic Uveal Melanoma Patients

Forschungsstelle

INNOSUISSE

Projektnummer

125.999 IP-LS

Projekttitel

Developing First-In-Class INPP5A Inhibitors as the First Effective Therapy for All GNAQ/11 Mutated Metastatic Uveal Melanoma Patients

Projekttitel Englisch

Developing First-In-Class INPP5A Inhibitors as the First Effective Therapy for All GNAQ/11 Mutated Metastatic Uveal Melanoma Patients

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Schlüsselwörter	-	-	-
Abstract	-	-	-

Kategorie	Text
Schlüsselwörter (Englisch)	Life sciences, Human medicine
Abstract (Englisch)	We aim to develop first-in-class effective small molecule inhibitor therapy for GNAQ/11 mutated uveal melanoma, the most common and lethal eye cancer. We found a novel and cancer specific target for a clearly defined patient population in this disease with high unmet need for therapeutics.